Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Ovarian Cancer|Triple Negative Breast Cancer
Interventions: BIOLOGICAL: Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.
Sponsor: Immune System Key Ltd